Effectiveness and safety of ustekinumab in Crohn's disease: short and long-term results of a multi-refractory cohort

被引：0
|
作者：
Aparicio-Serrano, A. [1 ]
Zamora Olaya, J. M. [1 ]
Ortiz Chimbo, D. S. [1 ]
Rodriguez Tirado, M. I. [1 ]
Gomez Perez, A. [1 ]
Soto Escribano, P. [1 ]
Marin Pedrosa, S. [1 ]
Iglesias Flores, E. [1 ]
Benitez, J. M. [1 ]
机构：
[1] Reina Sofia Univ Hosp, Gastroenterol & Hepatol, Cordoba, Spain
来源：
JOURNAL OF CROHNS & COLITIS | 2022年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P334
引用
收藏
页码：I351 / I352
页数：2
相关论文
共 50 条
  • [21] Real-world long-term effectiveness of ustekinumab in Crohn's disease: Results from the ENEIDA registry
    Iborra Colomino, M. I.
    Beltran, B.
    Fernandez-Clotet, A.
    Iglesias Flores, E.
    Navarro, P.
    Rivero, M.
    Gutierrez, A.
    Sierra-Ausin, M.
    Mesonero, F.
    Ferreiro-Iglesias, R.
    Hinojosa, J.
    Calvet, X.
    Sicilia, B.
    Gonzalez-Munoza, C.
    Antolin, B.
    Gonzalez Vivo, M.
    Carbajo, A. Y.
    Garcia, S.
    Martin-Cardona, A.
    Suris Marin, G.
    Martin-Arranz, M. D.
    De Francisco, R.
    Canete, F.
    Carlos, T.
    Gomollon, F.
    Lorente, R.
    Rodriguez-Lago, I.
    Fores-Bosch, A.
    Bernardos, E.
    Ramos, L.
    Delgado, P.
    Hernandez, A.
    Van Domselaar, M.
    Hervas, D.
    Domenech, E.
    Nos, P.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S458 - S460
  • [22] ASSOCIATION OF USTEKINUMAB TROUGH AND CRP LEVEL WITH LONG-TERM EFFECTIVENESS IN CROHN'S DISEASE
    Hosomi, Shuhei
    Okuda, Hiroaki
    Kurimoto, Noriyuki
    Kobayashi, Yumie
    Nakata, Rieko
    Nishida, Yu
    Ominami, Masaki
    Nadatani, Yuji
    Fukunaga, Shusei
    Otani, Koji
    Kamata, Noriko
    Tanaka, Fumio
    Nagami, Yasuaki
    Taira, Koichi
    Fujiwara, Yasuhiro
    GASTROENTEROLOGY, 2022, 162 (07) : S1097 - S1097
  • [23] Short-and long-term effectiveness of ustekinumab in patients with Crohn's disease: real-world data from a German IBD cohort
    Kubesch, A.
    Rueter, L.
    Farrag, K.
    Krause, T.
    Stienecker, K.
    Hausmann, J.
    Filmann, N.
    Dignass, A.
    Stein, J.
    Blumenstein, I.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S405 - S405
  • [24] Effectiveness, safety and persistence of treatment with ustekinumab in a cohort of patients with moderate-to-severe refractory Crohn's Disease
    Morales Bermudez, A. I.
    Bravo Aranda, A. M.
    Martinez Burgos, M.
    Olmedo Martin, R.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S509 - S510
  • [25] Long-Term Effectiveness and Safety of Ustekinumab for The Treatment of Crohn′s Disease: A Brazilian Multicentre Real-world Study
    Oleg, Knyazev
    Albina, Lishchinskaya
    Anatoliy, Konoplyannikov
    Anna, Kagramanova
    Nina, Fadeeva
    Dmitriy, Kulakov
    Anait, Babayan
    Mariya, Zvyaglova
    Asfold, Parfenov
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 : S2 - S2
  • [26] Real-world effectiveness and safety of risankizumab in patients with moderate-to-severe multi-refractory Crohn's disease: a Belgian multicentric cohort study
    Alsoud, D.
    Franchimont, D.
    D'Heygere, F.
    Bossuyt, P.
    Vijverman, A.
    Van Hootegem, P.
    Sabino, J.
    Cremer, A.
    Vermeire, S.
    Ferrante, M.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I516 - I517
  • [27] Real-world effectiveness and safety of ustekinumab for the treatment of Crohn's disease: the Scottish ustekinumab cohort
    Plevris, Nikolas
    Fulforth, James
    Siakavellas, Spyros
    Robertson, Andrew
    Hall, Rebecca
    Tyler, Amy
    Jenkinson, Philip W.
    Campbell, Iona
    Chuah, Cher Shiong
    Kane, Claire
    Veryan, Jennifer
    Lam, Wai Liam
    Saunders, Jayne
    Kelly, Christopher
    Gaya, Daniel
    Jafferbhoy, Hasnain
    Macdonald, Jonathan C.
    Seenan, John Paul
    Mowat, Craig
    Naismith, Graham
    Potts, Lindsay F.
    Sutherland, Diarmid Ian
    Watts, David
    Arnott, Ian
    Bain, Gillian
    Jones, Gareth
    Lees, Charlie W.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2021, 36 (08) : 2067 - 2075
  • [28] Real-world effectiveness and safety of risankizumab in patients with moderate-to-severe multi-refractory Crohn's disease: a Belgian multi-centric cohort study
    Alsoud, D.
    Franchimont, D.
    D'Heygere, F.
    Bossuyt, P.
    Vijverman, A.
    Van Hootegem, P.
    Sabino, J.
    Cremer, A.
    Vermeire, S.
    Ferrante, M.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I516 - I517
  • [29] LONG-TERM EFFICACY AND SAFETY OF USTEKINUMAB FOR CROHN'S DISEASE: RESULTS FROM IM-UNITI LONG-TERM EXTENSION THROUGH TWO YEARS
    Sandborn, William J.
    Rutgeerts, Paul
    Gasink, Christopher
    Jacobstein, Douglas
    Gao, Long-Long
    Johanns, Jewel
    Sands, Bruce E.
    Hanauer, Stephen B.
    Targan, Stephan R.
    Ghosh, Subrata
    de Villiers, Willem J.
    Colombel, Jean Frederic
    Feagan, Brian G.
    GASTROENTEROLOGY, 2017, 152 (05) : S585 - S585
  • [30] LONG-TERM CUMULATIVE SAFETY USTEKINUMAB IN BIONAIVE PATIENTS WITH CROHN'S DISEASE AND ULCERATIVE COLITIS
    Sands, Bruce E.
    Hanauer, Stephen B.
    Jairath, Vipul
    Mihaly, Emese
    Vicente, Raquel
    Ott, Elyssa
    Gasink, Christopher
    Miao, Ye
    Ma, Tony
    Marano, Colleen W.
    Danese, Silvio
    GASTROENTEROLOGY, 2022, 162 (07) : S960 - S961
12345